Arrowhead Pharmaceuticals, Inc. $ARWR Shares Bought by Northwestern Mutual Wealth Management Co.

Northwestern Mutual Wealth Management Co. boosted its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 178,519.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 421,543 shares of the biotechnology company’s stock after acquiring an additional 421,307 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Arrowhead Pharmaceuticals were worth $27,986,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. M&T Bank Corp boosted its holdings in shares of Arrowhead Pharmaceuticals by 2,569.6% in the 4th quarter. M&T Bank Corp now owns 240,634 shares of the biotechnology company’s stock valued at $15,976,000 after buying an additional 231,620 shares in the last quarter. Erste Asset Management GmbH boosted its stake in Arrowhead Pharmaceuticals by 55.3% during the 3rd quarter. Erste Asset Management GmbH now owns 73,000 shares of the biotechnology company’s stock worth $2,466,000 after purchasing an additional 26,000 shares during the period. Johnson Investment Counsel Inc. purchased a new position in Arrowhead Pharmaceuticals during the 3rd quarter worth $781,000. Vanguard Personalized Indexing Management LLC purchased a new position in Arrowhead Pharmaceuticals during the 3rd quarter worth $287,000. Finally, Fisher Asset Management LLC raised its position in Arrowhead Pharmaceuticals by 133.3% during the 3rd quarter. Fisher Asset Management LLC now owns 1,053,794 shares of the biotechnology company’s stock worth $36,345,000 after buying an additional 602,139 shares during the last quarter. Institutional investors and hedge funds own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Trading Down 1.0%

NASDAQ:ARWR opened at $73.18 on Wednesday. The company has a debt-to-equity ratio of 1.41, a current ratio of 6.23 and a quick ratio of 6.23. Arrowhead Pharmaceuticals, Inc. has a fifty-two week low of $14.30 and a fifty-two week high of $82.26. The stock’s 50-day moving average is $66.41 and its two-hundred day moving average is $62.48. The stock has a market cap of $10.31 billion, a PE ratio of -34.04 and a beta of 1.28.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) EPS for the quarter, beating the consensus estimate of ($1.10) by $0.17. The business had revenue of $73.74 million during the quarter, compared to analysts’ expectations of $73.84 million. Arrowhead Pharmaceuticals had a negative return on equity of 55.09% and a negative net margin of 48.38%.The firm’s quarterly revenue was down 86.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.75 EPS. As a group, equities research analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.94 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Daniel Joseph Apel sold 13,095 shares of the company’s stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $71.35, for a total value of $934,328.25. Following the completion of the transaction, the chief financial officer directly owned 162,905 shares in the company, valued at approximately $11,623,271.75. This represents a 7.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Hongbo Lu sold 2,970 shares of the company’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $76.88, for a total transaction of $228,333.60. Following the completion of the sale, the director directly owned 52,012 shares in the company, valued at approximately $3,998,682.56. The trade was a 5.40% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 36,065 shares of company stock valued at $2,554,562. 3.60% of the stock is owned by company insiders.

Analyst Ratings Changes

ARWR has been the subject of a number of research analyst reports. Royal Bank Of Canada increased their price target on shares of Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the company an “outperform” rating in a report on Friday, May 8th. Morgan Stanley raised shares of Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $78.00 to $100.00 in a research note on Tuesday, April 21st. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, May 6th. JPMorgan Chase & Co. assumed coverage on shares of Arrowhead Pharmaceuticals in a research report on Friday, May 1st. They issued an “overweight” rating and a $88.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $100.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, March 25th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, Arrowhead Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $87.80.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.